Search Result

Results for "

cdk2+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Angiotensin-converting Enzyme (ACE) (1) Apoptosis (14) Aurora Kinase (1) Autophagy (2) Bcl-2 Family (2) Carbonic Anhydrase (2) Caspase (2) CDK (71) Drug Intermediate (1) Drug Isomer (1) EGFR (2) FLT3 (1) GSK-3 (2) Isotope-Labeled Compounds (2) JAK (1) MDM-2/p53 (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) VEGFR (3) Wee1 (1)
By Research Areas:	Cancer (70) Cardiovascular Disease (1) Infection (2) Neurological Disease (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-162001

INX-315 5+ Cited Publications	CDK	Cancer
INX-315 is an orally active and selective *CDK2* inhibitor that induces cell cycle arrest in the G1 phase. INX-315 reduces *CDK2* substrate phosphorylation and inhibits tumor growth in a dose-dependent manner in xenograft mouse models. INX-315 may be used in cancer research .

HY-18629

SU9516 5 Publications Verification	CDK Autophagy Apoptosis	Cancer
SU9516 is a potent *CDK2* inhibitor, with an IC₅₀ of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC₅₀s of 40, 200 nM, respectively.

HY-158106

AZD8421 1 Publications Verification	CDK	Cancer
AZD8421 is a selective *CDK2* inhibitor (IC₅₀ = 9 nM) as well as achieving CDK family selectivity in cells versus key off-targets (CDK1, CDK4/6, CDK9), AZD8421 had no significant kinase inhibition outside the CDK family. AZD8421 inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest in G1/S phase and senescence. AZD8421 can be studied in research for breast cancer and ovarian cancer .

HY-15339

CVT-313 Maximum Cited Publications 9 Publications Verification cdk2 Inhibitor III	CDK	Cancer
CVT-313 (Cdk2 Inhibitor III) is a potent, selective, reversible, and ATP-competitive inhibitor of *CDK2* with IC₅₀ of 0.5 μM. CVT-313 inhibits CDC5L phosphorylation .

HY-18930

NU6300	CDK	Cancer
NU6300 is a covalent, irreversible and ATP-competitive *CDK2* inhibitor with an IC₅₀ value of 0.16 μM. NU6300 can be used for the research of eukaryotic cell cycle- and transcription-related .

HY-160701

Cirtociclib 2 Publications Verification BLU-222	CDK Apoptosis	Cancer
Cirtociclib (BLU-222) is an orally active and highly selective *CDK2* inhibitor. Cirtociclib disrupts Rb signaling and causes G1 arrest and apoptosis in CCNE1-amplified endometrial cancer cells ^[2] .

HY-15275

BMS-265246 2 Publications Verification	CDK Angiotensin-converting Enzyme (ACE)	Infection Cardiovascular Disease Cancer
BMS-265246 is a potent and selective cyclin-dependent kinase CDK1 and *CDK2* inhibitor, with IC₅₀ values of 6 and 9 nM, respectively. BMS-265246 inhibits CHI3L1 (chitinase 3-like-1) stimulation of *ACE2* (angiotensin converting enzyme 2) and SPP (viral spike protein priming proteases). BMS-265246 can be used for ovarian cancer and COVID-19 research ^[2] .

HY-15569

NU6102	CDK	Cancer
NU6102 is a potent CDK1 and *CDK2* inhibitor with IC₅₀s of 9.5 nM and 5.4 nM for CDK1/cyclinB and *CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2* over CDK4 (IC₅₀ of 1.6 μM), DYRK1A (IC₅₀ of 0.9 μM), PDK1 (IC₅₀ of 0.8 μM) and ROCKII (IC₅₀ of 0.6 μM) ^[2].

HY-15004

AUZ 454 5+ Cited Publications K03861	CDK	Cancer
AUZ 454 (K03861) is a type II *CDK2* inhibitor with K_d of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.

HY-164664

CDK2-IN-30	CDK	Cancer
CDK2-IN-30 is a *CDK2* inhibitor with an IC₅₀ value ≤20 nM. CDK2-IN-30 modulates CDK2 activity to influence cell cycle regulation. CDK2-IN-30 can be used for the research of cancer .

HY-117535

CDK2-IN-4 3 Publications Verification	CDK	Cancer
CDK2-IN-4 (compound 73) is a potent and selective *CDK2* inhibitor with an IC₅₀ of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC₅₀=86 uM) .

HY-112358

GW8510	CDK	Neurological Disease Cancer
GW8510 is a potent cyclin-dependent kinase-2 (CDK2) inhibitor. GW8510 is also a ribonucleotide reductase M2 (RRM2) inhibitor. GW8510 exhibits neuroprotective and anticancer activities ^[2] .

HY-103647

K00546	CDK VEGFR GSK-3	Cancer
K00546 is a potent CDK1 and *CDK2* inhibitor with IC₅₀s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC₅₀s of 8.9 nM and 29.2 nM, respectively ^[2] .

HY-15163

Zotiraciclib 2 Publications Verification TG02; SB1317	JAK CDK FLT3	Cancer
Zotiraciclib (TG02; SB1317) is an orally active *JAK2/FLT3/CDK2** inhibitor* with IC₅₀ values of 13 nM, 73 nM and 56 nM , respectively. Zotiraciclib inhibits cancer cell proliferation, tumor growth and the activity of *CYP2D6. Zotiraciclib exhibits high plasma protein binding rate, Caco-2 permeability and tissue distribution capacity, as well as metabolic stability in human and canine liver microsomes. Zotiraciclib achieves tumor growth inhibition in nude mouse models of colon cancer and lymphoma xenografts. Zotiraciclib can be used for research related to colon cancer, B-cell lymphoma*, advanced leukemia, acute leukemia and multiple myeloma ^[2].

HY-112460

CDK2-IN-3	CDK	Cancer
CDK2-IN-3 (compound 3) is a potent and selective *CDK2* inhibitor with an IC₅₀ of 60 nM .

HY-100600

BGG463 K03859	CDK	Others
BGG463 (K03859) is an orally active type II *CDK2* inhibitor .

HY-162255

CDK2-IN-23	CDK	Cancer
CDK2-IN-23 (Compound 17) is a kinase selective and highly potent *CDK2* inhibitor (IC₅₀ = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .

HY-W478102

CDK2-IN-13	CDK	Cancer
CDK2-IN-13 (Compound 15) is a *CDK2* inhibitor with an IC₅₀ of 12 µM. CDK2-IN-13 can be used in research of cancer .

HY-W002616

5-Bromoindolin-2-one 5-Bromooxindole	Drug Intermediate	Infection
5-Bromoindolin-2-one (5-Bromooxindole) is a synthetic intermediate. 5-Bromoindolin-2-one can be used for the synthesis of CDK2 inhibitors and antibacterial agents .

HY-157516

CDK2-IN-22	CDK	Cancer
CDK2-IN-22 (compound 7I) is a potent *CDK2* inhibitor with an IC₅₀ of 64.42 nM. CDK2-IN-22 presents a broad antiproliferative efficacy toward diverse cancer cells MV4-11, HT-29, MCF-7, and HeLa with IC₅₀ values of 0.83 μM, 2.12 μM, 3.12 μM, and 8.61 μM, respectively .

HY-112471

TrkA Inhibitor	CDK	Cancer
TrkA Inhibitor (Compound 18) is a *CDK2* inhibitor with an IC₅₀ of 0.69  μM over CDK1. TrkA Inhibitor can be used for chemotherapy-induced alopecia research .

HY-P3730

Cdk2/Cyclin Inhibitory Peptide I	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a *CDK2* inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-123045

PNU-292137	CDK	Cancer
PNU-292137 is an orally active, potent *CDK2* inhibitor with IC₅₀s of 37 nM and 92 nM for CDK2/cyclin A and CDK2/cyclin E, respectively. PNU-292137 makes interactions with the hydrophobic pocket at the back of the CDK2 ATP pocket. PNU-292137 efficiently inhibits tumor cell proliferation in human colon and prostate tumor cell lines. PNU-292137 exhibits antitumor activity (TGI>50%) in a mouse xenograft model .

HY-151580S

CDK2-IN-14-d3	CDK	Cancer
CDK2-IN-14-d₃ is a potent and selective CDK2 inhibitor. CDK2-IN-14-d₃ can be used in research of cancer .

HY-151573

EGFR/CDK2-IN-1	EGFR CDK	Cancer
EGFR/CDK2-IN-1 (Compound 3b) is an *EGFR/CDK2* inhibitor. EGFR/CDK2-IN-1 shows good cytotoxicity against MCF7 and HepG2 cells. EGFR/CDK2-IN-1 can be used in cancer research .

HY-161690

EF-4-177	CDK	Others
EF-4-177 is an orally active and allosteric *CDK2* inhibitor with the IC₅₀ of 87 nM. EF-4-177 can disrupt spermatogenesis ^[2].

HY-151580

CDK2-IN-14	CDK	Cancer
CDK2-IN-14 (compound 4f) is a highly selective *CDK2* inhibitor. CDK2-IN-14 can be used in research of cancer .

HY-162528

CDK12-IN-7	CDK	Cancer
CDK12-IN-7 (Compound 2) is a CDK12 and *CDK2* inhibitor with IC₅₀ values of 42 and 196 nM, respectively. CDK12-IN-7 has anti-cell proliferation activity and can be used in cancer research .

HY-178756

CDK2-IN-48	CDK	Cancer
CDK2-IN-48 (Compound 109) is a *CDK2* inhibitor with IC₅₀ values for *CDK2* and CDK1 of respectively < 0.05 and > 1 μM. CDK2-IN-48 can be used for the study of CDK2-dependent cancers .

HY-178112

CDK2-IN-47	CDK Apoptosis	Cancer
CDK2-IN-47 is a potent *CDK2* inhibitor with an IC₅₀ of 0.21 μM. CDK2-IN-47 exhibits outstanding anticancer activity against MCF-7, HCT-116, and MGC-803 cell lines. CDK2-IN-47 effectively induces G1 cell cycle arrest, retinoblastoma protein (Rb) dephosphorylation, and significant apoptosis. CDK2-IN-47 can be used for the studies of breast cancer, colorectal cancer and gastric cancer .

HY-153221

QR-6401	CDK	Cancer
QR-6401 is an orally active and selective macrocyclic *CDK2* inhibitor with IC₅₀ values of 0.37, 10, 22, 34 and 45 nM for *CDK2/E1, CDK9/T1, CDK1/A2, CDK6/D3* and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .

HY-169683

CDK2-IN-39	CDK	Cancer
CDK2-IN-39 (compound 4) is a *CDK2* inhibitor .

HY-139651

CDK2-IN-7	CDK	Cancer
CDK2-IN-7 is a *CDK2* inhibitor for researching cancer (IC₅₀ < 50 nM).

HY-170441

CDK2-IN-36	CDK	Cancer
CDK2-IN-36 (compound1) is a *CDK2* inhibitor with anticancer activity .

HY-161291

CDK2-IN-25	CDK	Cancer
CDK2-IN-25 (compound 7e) is a CDK2 inhibitor with an IC₅₀ of 0.149 μM .

HY-170306

LZ9	CDK	Cancer
LZ9 is a ATP-competitive CDK1 and *CDK2* inhibitor. LZ9 has the potential for the research of colorectal cancer (CRC) ^[2].

HY-162683A

(R)-PHA533533	CDK Drug Isomer	Cancer
(R)-PHA533533 is an inactive enantiomer (S)-PHA533533 (active enantiomer) (HY-162683). (S)-PHA533533 is a CDK2 inhibitor with antitumor activity .

HY-P3731

Cdk2/Cyclin Inhibitory Peptide II	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a *CDK2* inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-115943

Anticancer agent 30	CDK	Cancer
Anticancer agent 30 (compound 6f-Z), a 3-arylidene-2-oxindole derivative, is a selective *CDK2* inhibitor with potent anticancer activity .

HY-155966

CDK2-IN-19	CDK	Cancer
CDK2-IN-19 (Compound 32) is a selective and orally active *CDK2* inhibitor (K_i: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors .

HY-169246

CDK2-IN-32	CDK Apoptosis	Cancer
CDK2-IN-32 (Compound 5g) is a selective *CDK2* inhibitor with an IC₅₀ of 0.21 μM. CDK2-IN-32 shows cytotoxicity against Vero cells with an IC₅₀ of 28.52 μM .

HY-144810

CDK2-IN-8	CDK	Cancer
CDK2-IN-8 is a potent *CDK2* inhibitor with an IC₅₀ of 1.74 µM. CDK2-IN-8 shows antiproliferative activity. CDK2-IN-8 has the potential for the research of melanoma .

HY-160643

CDK2-IN-27	CDK	Cancer
CDK2-IN-27 (compound 1) is a potent *CDK2* inhibitor with IC₅₀ values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively .

HY-15570

NU6301	CDK	Cancer
NU6301 is a NU6102 (a CDK2 inhibitor) (HY-15569) prodrug. NU6301 can rapidly generate NU6102 in mouse plasma. NU6301 has anticancer activity against endometrial cancer .

HY-161463

CDK2-IN-28	CDK	Cancer
CDK2-IN-28 (compound 22) is a *CDK2* inhibitor with good selectivity and cellular effects against other CDKs. CDK2-IN-28 has anti-proliferative effects on MKN1 cells (EC50: 0.31 μM) .

HY-168067

CDK-IN-14	CDK Caspase Apoptosis	Cancer
CDK-IN-14 (B34) is a *CDK2* inhibitor (IC₅₀=0.097 μM) with anti-hepatocellular carcinoma activity. CDK-IN-14 blocks the cell cycle of HepG-2 cancer cells through a caspase-mediated mechanism and induces apoptosis .

HY-18629A

(E/Z)-SU9516	Apoptosis CDK Autophagy	Cancer
(E/Z)-SU9516 is the isomer of SU9516 (HY-18629). SU9516 is a potent *CDK2* inhibitor，with an IC₅₀ of 22 nM，and also shows inhibitory effects on CDK1 and CDK4，with IC₅₀s of 40，200 nM，respectively.

HY-150572

CDK2-IN-11	CDK Carbonic Anhydrase	Cancer
CDK2-IN-11 (compound 9d) is a potent *CDK2* inhibitor with an IC₅₀ of 6.4 μM, and K_I values of 23.4 nM, 56.3 nM and 44.3 nM for hCA II, hCA IX and hCA XII, respectively. CDK2-IN-11 can be used for researching anticancer .

HY-W478102S

CDK2-IN-13-d3	Isotope-Labeled Compounds CDK	Cancer
CDK2-IN-13-d₃ is the deuterium labeled CDK2-IN-13 (HY-W478102). CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC₅₀ of 12 μM. CDK2-IN-13 can be used in research of cancer .

HY-150573

CDK2-IN-12	CDK Carbonic Anhydrase	Cancer
CDK2-IN-12 (compound 10b) is a potent *CDK2* inhibitor, with an IC₅₀ of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with K_I values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-149436

CDK2/Bcl2-IN-1	Terpenoids Zygophyllaceae Diterpenoids Plants Zygophyllum album L.f. Source Classification	CDK
CDK2/Bcl2-IN-1 (compound 1), a saponin and a CDK-2 inhibitor (IC₅₀=117.6 nM) with promising cytotoxicity against cancer cells. CDK2/Bcl2-IN-1 also inhibits Bcl-2, and induces apoptosis in A549 lung cancer cells .

Cat. No.	Product Name	Chemical Structure

HY-151580S

CDK2-IN-14-d3
CDK2-IN-14-d₃ is a potent and selective CDK2 inhibitor. CDK2-IN-14-d₃ can be used in research of cancer .

HY-W478102S

CDK2-IN-13-d3
CDK2-IN-13-d₃ is the deuterium labeled CDK2-IN-13 (HY-W478102). CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC₅₀ of 12 μM. CDK2-IN-13 can be used in research of cancer .

HY-176174S

CDK2-IN-46
CDK2-IN-46 (compound 5g) is a selective *CDK2* inhibitor with an IC₅₀ of 0.3 nM. CDK2-IN-46 has a selectivity of >200-fold for CDK1, CDK7, CDK9, CDK4, and CDK6. CDK2-IN-46 shows improves rat and cyno pharmacokinetic profiles .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

cdk2+inhibitor

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products